{
  "authors": [
    {
      "author": "Rena A Shah"
    },
    {
      "author": "Daniel D Bennett"
    },
    {
      "author": "Mark E Burkard"
    }
  ],
  "doi": "10.1186/s12885-017-3882-4",
  "publication_date": "2017-12-21",
  "id": "EN113608",
  "url": "https://pubmed.ncbi.nlm.nih.gov/29258457",
  "source": "BMC cancer",
  "source_url": "",
  "licence": "CC BY",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "Seventy-threeÂ year old female with a diagnosis of stage IV breast cancer undergoing management with capecitabine presents with a rash during the summer months that is biopsy proven to be lichenoid photosensitive rash with likely offending agent being capecitabine. Her treatment was initially held despite having response to treatment, started on topical steroids after evaluation by dermatology. Given her response to treatment, drug was resumed with instructions to use sun precaution, sunscreen, and to complete course of topical steroids until rash resolution."
}